Nov outside outside Aus and Multiple Dec Oct Lenalidomide 13 Yes 23 None 2008, funding Sept 2014 funding NZ myeloma 2007 2008 extension restrictions restrictions in Nov 2015 no Aus and resistant Jan no no Lenvatinib 3 Yes 3 None no funding no funding NZ thyroid 2016 registration registration cancer Chronic outside outside Aus and Jan August Nilotinib Tasigna® 11 Yes myeloid 6 None in funding Oct 2014 funding NZ 2008 2010 leukaemia March restrictions restrictions 2008 in Non-small Sept March no March no Nintedanib Ofev® Aus 2 Yes cell lung 6 None no funding 2015 2015 and registration 2016 registration cancer March 2016 Metastatic melanoma; metastatic non-small cell lung Aus and cancer; Feb no April no Nivolumab* Opdivo® 17 Yes 110 None no funding no funding NZ metastatic 2016 registration 2016 registration renal cell cancer; classical Hodgkins lymphoma
Lenalidomide Aus and NZ 13 Yes Multiple myeloma 23 None Dec 2007 Nov 2008, extension in Nov 2015 outside funding restrictions Oct 2008 Sept 2014 outside funding restrictions Lenvatinib Aus and NZ 3 Yes thyroid cancer 3 None Jan 2016 no funding no registration no no funding no registration Nilotinib Tasigna® Aus and NZ 11 Yes Chronic myeloid leukaemia 6 None Jan 2008 in March 2008 outside funding restrictions August 2010 Oct 2014 outside funding restrictions Nintedanib Ofev® Aus 2 Yes Non-small cell lung cancer 6 None Sept 2015 in March 2015 and March 2016 no registration March 2016 no funding no registration Nivolumab* Opdivo® Aus and NZ 17 Yes Metastatic melanoma; metastatic non-small cell lung cancer; metastatic renal cell cancer; classical Hodgkins lymphoma 110 None Feb 2016 no funding no registration April 2016 no funding no registration resistant
1-s2.0-S0168851017303457-mmc1.docx